Guardant Health, INC Form 4 insider transactions

Director Steve Krognes sold 9,294 shares of Guardant Health, Inc. common stock on June 4, 2026.

Director Meghan V. Joyce exercised stock options and sold 10,000 shares of Guardant Health, Inc. common stock.

Director Steve Krognes acquired 154 shares of Guardant Health common stock through the vesting of restricted stock units.

Director Manuel Hidalgo Medina sold 1,000 shares of Guardant Health, Inc. (GH) common stock on May 28, 2026.

John G. Saia, Chief Legal Officer of Guardant Health, Inc., sold 10,000 shares of common stock on May 27, 2026.

Chris Freeman, Chief Commercial Officer at Guardant Health, Inc., reported the sale of 24,406 shares of common stock on May 22, 2026.

Guardant Health's Chief Legal Officer, John G. Saia, sold 19,000 shares of common stock in pre-planned transactions under a Rule 10b5-1 plan.

Guardant Health Co-Chief Executive Officer AmirAli Talasaz sold 210,000 shares of common stock for over $22.7 million through a pre-arranged 10b5-1 plan.

Guardant Health Director Ian T. Clark sold 6,876 shares of common stock for approximately $106.90 per share in a pre-planned transaction.

Guardant Health Director Manuel Hidalgo Medina exercised stock options and sold a portion of his common stock holdings.

Director Tariq Musa reported the vesting of restricted stock units and a subsequent sale of common stock in Guardant Health, Inc.

Director Manuel Hidalgo Medina acquired 232 shares of Guardant Health, Inc. common stock through the vesting of restricted stock units.

Guardant Health Chief Technology Officer Darya Chudova acquired 8,705 shares via RSU vesting, with 4,679 shares withheld for taxes.

Co-CEO AmirAli Talasaz sold 50,000 shares of Guardant Health common stock via a pre-arranged 10b5-1 trading plan.

Director Steve Krognes acquired 154 shares of Guardant Health common stock through the vesting of restricted stock units.

Director Roberto Mignone acquired 264 shares of Guardant Health common stock through the vesting of restricted stock units.

Director Manuel Hidalgo Medina acquired 232 shares of Guardant Health, Inc. common stock through the vesting of restricted stock units.

Director Tariq Musa acquired 250 shares of Guardant Health via RSU vesting and sold 116 shares to cover tax obligations.

Chief Legal Officer John G. Saia acquired 7,569 shares of Guardant Health common stock through the vesting of restricted stock units.

Guardant Health Chief People Officer Terilyn J. Monroe reported a sale of 3,832 shares of common stock on April 6, 2026, for $92.68 per share.

Guardant Health's Chief Legal Officer, John G. Saia, reported transactions involving the acquisition of common stock and vesting of restricted stock units.

Guardant Health Chief People Officer Terilyn J. Monroe reported transactions involving restricted stock units and common stock.

Guardant Health, Inc. (GH) Chief Information Officer Kumud Kalia reported transactions involving restricted stock units and common stock.

Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported transactions involving restricted stock units and common stock.

Guardant Health's Chief Medical Officer, Craig Eagle, reported on April 1, 2026, regarding the vesting of restricted stock units and associated tax withholding.

Darya Chudova, Chief Technology Officer at Guardant Health, Inc., reported transactions involving the acquisition of common stock and restricted stock units.

Guardant Health CFO Michael Brian Bell reported transactions involving restricted stock units and common stock, including shares retained for tax withholding.

Guardant Health, Inc. executive AmirAli Talasaz reported transactions involving common stock and restricted stock units, including acquisitions and dispositions related to vesting and tax withholding.

Guardant Health Co-CEO Helmy Eltoukhy reported transactions involving the acquisition of company stock, including shares from vested Restricted Stock Units and shares retained for tax withholding.

Guardant Health Director Steve E. Krognes reported the acquisition of 155 shares of common stock through the vesting of restricted stock units.